中国肺癌杂志2011，Vol.14Issue(2)：127-131,5.DOI:10.3779/j.issn.1009-3419.2011.02.04
晚期肺腺癌患者化疗前后血清EGFR基因突变状态的比较
Comparison of EGFR Mutation Status in Paired Pre- and Post-chemotherapy Serum for Advanced Pulmonary Adenocarcinoma
韩如冰 1钟巍 1赵静 1张力 1夏莹 1王寒 1李龙芸 1王孟昭1
作者信息
- 1. 100730,北京,中国医学科学院,北京协和医学院,北京协和医院呼吸科
- 折叠
摘要
Abstract
Background and objective Non-small cell lung cancer (NSCLC) with mutations in the epidermal growth factor receptor (EGFR) is a distinct subgroup of NSCLC, which is particularly responsive to EGFR tyrosine kinase inhibitors (TKIs).Ihe aim of this study is to detect EGFR mutations in paired serum of pre- and post-chemotherapy from advanced pulmonary adenocarcinoma patients to evaluate impact of chemotherapy on EGFR mutation status.Methods Magnetic beads were used for DNA extraction from paired serum of pre- and post-chemotherapy of 33 advanced pulmonary adenocarcinoma patients.The EGFR exon 19 and 21 were amplified by mutant-enriched nested PCR and analyzed by direct sequencing.Results EGFR mutations were detected in 39.4％ (13/33) and 54.5％ (18/33) serum samples of pre- and postchemotherapy, respectively.The EGFR mutation status was consistent in 54.5％ (18/33) patients.Among 15 discordant cases,10 changed from pre-chemo wild-type to post-chemo mutant-type status, while 5 from pre-chemo mutant-type to post-chemo wild-type status.Conclusion Chemotherapy may have influence on serum EGFR mutation status in advanced adenocacinoma patients.关键词
肺肿瘤/突变/化疗分类
医药卫生引用本文复制引用
韩如冰,钟巍,赵静,张力,夏莹,王寒,李龙芸,王孟昭..晚期肺腺癌患者化疗前后血清EGFR基因突变状态的比较[J].中国肺癌杂志,2011,14(2):127-131,5.
